Recursion: Undruggable CDK12 Protein Target Might Be Possible With REC-1245
Portfolio Pulse from
Recursion Pharmaceuticals is advancing its drug candidates, REC-994 and REC-1245, targeting cerebral cavernous malformation and biomarker-enriched solid tumors/lymphomas, respectively. The company plans to meet with the FDA regarding REC-994 and expects data from REC-1245's phase 1/2 study by 2025-2026.
December 09, 2024 | 8:30 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Recursion Pharmaceuticals is progressing with its drug candidates REC-994 and REC-1245. The company plans to meet with the FDA about REC-994 and expects phase 1/2 study data for REC-1245 by 2025-2026.
The news highlights Recursion's progress in drug development, which is crucial for its growth and investor interest. The upcoming FDA meeting and expected study data are positive indicators for the company's future prospects.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100